In the recent DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) study, Dapagliflozin reduced the risk of death and worsening heart failure and improved symptoms across the broad spectrum of age including elderly individuals.

 

Recent findings from the Colchicine Cardiovascular Outcomes Trial found that among patients with a recent myocardial infarction, colchicine (an orally administered antiinflammatory medication indicated for the treatment of gout and pericarditis) at a dose of 0.5 mg daily led to much lower risk of ischemic cardiovascular events than placebo.

Recently the FDA has stated to continue efforts “to bring competition to the insulin market to lower prices and expand access”, with biosimilar insulins taking center-stage

Meet Dr. Pamela B. Morris, MD--the current Director of Preventive Cardiology and the Seinsheimer Cardiovascular Health Program and Co-Director of Women's Heart Care at the Medical University of South Carolina. Among her many passions and accomplishments, Dr. Morris has had a career long interest in educating physicians and patients across the nation on sex-specific issues in cardiovascular care.